vs

Side-by-side financial comparison of CROWN CRAFTS INC (CRWS) and Avidity Biosciences, Inc. (RNA). Click either name above to swap in a different company.

CROWN CRAFTS INC is the larger business by last-quarter revenue ($20.7M vs $12.5M, roughly 1.7× Avidity Biosciences, Inc.). CROWN CRAFTS INC runs the higher net margin — 7.3% vs -1398.3%, a 1405.6% gap on every dollar of revenue. On growth, Avidity Biosciences, Inc. posted the faster year-over-year revenue change (434.0% vs -11.3%). CROWN CRAFTS INC produced more free cash flow last quarter ($2.3M vs $-156.9M). Over the past eight quarters, Avidity Biosciences, Inc.'s revenue compounded faster (138.5% CAGR vs -6.7%).

Crown Crafts is a publicly held American company headquartered in Gonzales, Louisiana. The company designs, markets and distributes infant, toddler and juvenile consumer products. Its stock is traded on the NASDAQ Capital Market under the ticker symbol "CRWS".

Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.

CRWS vs RNA — Head-to-Head

Bigger by revenue
CRWS
CRWS
1.7× larger
CRWS
$20.7M
$12.5M
RNA
Growing faster (revenue YoY)
RNA
RNA
+445.3% gap
RNA
434.0%
-11.3%
CRWS
Higher net margin
CRWS
CRWS
1405.6% more per $
CRWS
7.3%
-1398.3%
RNA
More free cash flow
CRWS
CRWS
$159.2M more FCF
CRWS
$2.3M
$-156.9M
RNA
Faster 2-yr revenue CAGR
RNA
RNA
Annualised
RNA
138.5%
-6.7%
CRWS

Income Statement — Q3 FY2026 vs Q3 FY2025

Metric
CRWS
CRWS
RNA
RNA
Revenue
$20.7M
$12.5M
Net Profit
$1.5M
$-174.4M
Gross Margin
23.5%
Operating Margin
-0.5%
-1513.5%
Net Margin
7.3%
-1398.3%
Revenue YoY
-11.3%
434.0%
Net Profit YoY
69.1%
-117.0%
EPS (diluted)
$-1.27

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CRWS
CRWS
RNA
RNA
Q4 25
$20.7M
Q3 25
$23.7M
$12.5M
Q2 25
$15.5M
$3.8M
Q1 25
$23.2M
$1.6M
Q4 24
$23.4M
$3.0M
Q3 24
$24.5M
$2.3M
Q2 24
$16.2M
$2.0M
Q1 24
$3.5M
Net Profit
CRWS
CRWS
RNA
RNA
Q4 25
$1.5M
Q3 25
$1.2M
$-174.4M
Q2 25
$-1.1M
$-157.3M
Q1 25
$-10.8M
$-115.8M
Q4 24
$893.0K
$-102.3M
Q3 24
$860.0K
$-80.4M
Q2 24
$-322.0K
$-70.8M
Q1 24
$-68.9M
Gross Margin
CRWS
CRWS
RNA
RNA
Q4 25
23.5%
Q3 25
27.7%
Q2 25
22.7%
Q1 25
18.3%
Q4 24
26.1%
Q3 24
28.4%
Q2 24
24.5%
Q1 24
Operating Margin
CRWS
CRWS
RNA
RNA
Q4 25
-0.5%
Q3 25
7.9%
-1513.5%
Q2 25
-7.7%
-4448.7%
Q1 25
-60.7%
-8360.9%
Q4 24
7.3%
-4069.6%
Q3 24
6.2%
-4200.9%
Q2 24
-1.8%
-4040.4%
Q1 24
-2178.6%
Net Margin
CRWS
CRWS
RNA
RNA
Q4 25
7.3%
Q3 25
4.9%
-1398.3%
Q2 25
-7.1%
-4089.3%
Q1 25
-46.4%
-7360.0%
Q4 24
3.8%
-3439.5%
Q3 24
3.5%
-3441.7%
Q2 24
-2.0%
-3461.8%
Q1 24
-1943.4%
EPS (diluted)
CRWS
CRWS
RNA
RNA
Q4 25
Q3 25
$-1.27
Q2 25
$-0.10
$-1.21
Q1 25
$-0.90
Q4 24
$-0.80
Q3 24
$-0.65
Q2 24
$-0.03
$-0.65
Q1 24
$-0.79

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CRWS
CRWS
RNA
RNA
Cash + ST InvestmentsLiquidity on hand
$2.4M
$350.2M
Total DebtLower is stronger
Stockholders' EquityBook value
$39.2M
$1.9B
Total Assets
$76.1M
$2.1B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CRWS
CRWS
RNA
RNA
Q4 25
$2.4M
Q3 25
$810.0K
$350.2M
Q2 25
$227.0K
$243.9M
Q1 25
$521.0K
$254.2M
Q4 24
$1.1M
$219.9M
Q3 24
$2.0M
$370.2M
Q2 24
$1.1M
$575.8M
Q1 24
$471.4M
Stockholders' Equity
CRWS
CRWS
RNA
RNA
Q4 25
$39.2M
Q3 25
$38.4M
$1.9B
Q2 25
$37.9M
$1.2B
Q1 25
$39.6M
$1.3B
Q4 24
$51.1M
$1.4B
Q3 24
$50.8M
$1.5B
Q2 24
$50.7M
$1.2B
Q1 24
$830.9M
Total Assets
CRWS
CRWS
RNA
RNA
Q4 25
$76.1M
Q3 25
$77.5M
$2.1B
Q2 25
$76.0M
$1.4B
Q1 25
$81.2M
$1.5B
Q4 24
$98.7M
$1.6B
Q3 24
$99.3M
$1.6B
Q2 24
$76.4M
$1.3B
Q1 24
$951.5M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CRWS
CRWS
RNA
RNA
Operating Cash FlowLast quarter
$2.7M
$-156.2M
Free Cash FlowOCF − Capex
$2.3M
$-156.9M
FCF MarginFCF / Revenue
11.3%
-1257.6%
Capex IntensityCapex / Revenue
1.7%
5.7%
Cash ConversionOCF / Net Profit
1.78×
TTM Free Cash FlowTrailing 4 quarters
$9.1M
$-592.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CRWS
CRWS
RNA
RNA
Q4 25
$2.7M
Q3 25
$-845.0K
$-156.2M
Q2 25
$5.2M
$-199.7M
Q1 25
$2.8M
$-124.8M
Q4 24
$-36.0K
$-99.9M
Q3 24
$-983.0K
$-65.6M
Q2 24
$8.0M
$-65.0M
Q1 24
$-70.4M
Free Cash Flow
CRWS
CRWS
RNA
RNA
Q4 25
$2.3M
Q3 25
$-1.0M
$-156.9M
Q2 25
$5.2M
$-203.0M
Q1 25
$2.6M
$-128.6M
Q4 24
$-220.0K
$-103.8M
Q3 24
$-1.2M
$-67.3M
Q2 24
$7.7M
$-65.5M
Q1 24
$-71.3M
FCF Margin
CRWS
CRWS
RNA
RNA
Q4 25
11.3%
Q3 25
-4.3%
-1257.6%
Q2 25
33.4%
-5277.1%
Q1 25
11.3%
-8174.3%
Q4 24
-0.9%
-3491.0%
Q3 24
-4.8%
-2881.8%
Q2 24
47.7%
-3204.6%
Q1 24
-2012.3%
Capex Intensity
CRWS
CRWS
RNA
RNA
Q4 25
1.7%
Q3 25
0.7%
5.7%
Q2 25
0.6%
86.9%
Q1 25
0.9%
238.6%
Q4 24
0.8%
131.7%
Q3 24
0.8%
72.9%
Q2 24
1.8%
26.0%
Q1 24
25.8%
Cash Conversion
CRWS
CRWS
RNA
RNA
Q4 25
1.78×
Q3 25
-0.73×
Q2 25
Q1 25
Q4 24
-0.04×
Q3 24
-1.14×
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons